Kyowa Kirin Reports Final German MINT Study Results for Mogamulizumab
Kyowa Kirin International announced final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides and Sézary syndrome.
Story updates
06:01:04 AM UTC
SquawkNews
Kyowa Kirin reported final German MINT real-world results for mogamulizumab in MF and Sézary syndrome: median TTNT 14.9 months, best overall response 62.4%, and median PFS 20.2 months in 109 patients.Material DetailsContext by AI AnalystThis is late-stage confirmation of efficacy and safety in a re…